title: [Experimental and clinical studies of sulbactam/cefoperazone in pediatric field].
abstract: Clinical trials were carried out with sulbactam/cefoperazone (SBT/CPZ) (combination ratio of 1:1) in pediatric infections. Results were as follows. The mean half-lives of SBT and CPZ in the serum following intravenous injection of SBT/CPZ were about 0.7 and 1.2 hours, respectively. Urinary excretions of SBT and CPZ within 6 hours after intravenous injection of SBT/CPZ were 81.9% and 28.1%, respectively. SBT/CPZ was administered to 33 pediatric patients with various infection; 18 respiratory tract infections, 12 urinary tract infections and 3 Salmonella enterocolitis. The overall efficacy rate was 87.9%. In particular, 7 of 8 urinary tract infections caused by beta-lactamase producing organisms were improved after administration of SBT/CPZ. Diarrhea in 8 and soft stool in 3 of 33 patients occurred, and slight elevation of GOT/GPT was observed in 2 patients.
mesh_terms: D000293:Adolescent; D000367:Age Factors; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002438:Cefoperazone / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D008297:Male; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D013407:Sulbactam; D065093:beta-Lactamase Inhibitors
chemical_list: D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D002438:Cefoperazone; D010397:Penicillanic Acid; D013407:Sulbactam